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Abstract.
Background: Current information is scarce regarding comorbid conditions, treatment, survival, institutionalization, and
health care utilization for Alzheimer’s disease (AD) patients.
Objectives: Compare all-cause mortality, rate of institutionalization, and economic burden between treated and untreated
newly-diagnosed AD patients.
Methods: Patients aged 65–100 years with ≥1 primary or ≥2 secondary AD diagnoses (ICD-9-CM:331.0] with continuous
medical and pharmacy benefits for ≥12 months pre-index and ≥6 months post-index date (first AD diagnosis date) were
identified from Medicare fee-for-service claims 01JAN2011–30JUN2014. Patients with AD treatment claims or AD/AD-
related dementia diagnosis during the pre-index period were excluded. Patients were assigned to treated and untreated cohorts
based on AD treatment received post-index date. Total 8,995 newly-diagnosed AD patients were identified; 4,037 (44.8%)
were assigned to the treated cohort. Time-to-death and institutionalization were assessed using Cox regression. To compare
health care costs and utilizations, 1 : 1 propensity score matching (PSM) was used.
Results:Untreated patients were older (83.85 versus 81.44 years; p < 0.0001), with more severe comorbidities (mean Charlson
comorbidity index: 3.54 versus 3.22; p < 0.0001). After covariate adjustment, treated patients were less likely to die (hazard
ratio[HR] = 0.69; p < 0.0001) and were associated with 20% lower risk of institutionalization (HR = 0.801; p = 0.0003). After
PSM, treated AD patients were less likely to have hospice visits (3.25% versus 9.45%; p < 0.0001), and incurred lower annual
all-cause costs ($25,828 versus $30,110; p = 0.0162).
Conclusion: After controlling for comorbidities, treated AD patients have better survival, lower institutionalization, and
sometimes fewer resource utilizations, suggesting that treatment and improved care management could be beneficial for
newly-diagnosed AD patients from economic and clinical perspectives.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by a
gradual decline in memory and cognitive skills that
limit a patient’s ability to perform daily activities
[1, 2]. An estimated 5.4 million US patients are
currently diagnosed with AD, with about 5 mil-
lion patients over age 65 [2, 3]. Age, genetics,
physical inactivity, unhealthy diet, and some cardio-
vascular diseases have been reported as significant
risk factors of AD [1]. With the aging US pop-
ulation, AD prevalence is expected to increase to
approximately 13 million by 2050 [2]. Currently,
no cure for AD exists. Existing treatments focus
on relieving symptoms and slowing symptom pro-
gression, maintaining cognitive and daily function,
and managing behavioral symptoms [4]. So far,
four medications (donepezil, rivastigmine, galan-
tamine, and memantine) have been approved for AD
management [2].
AD is also known to be one of the main causes of
disability and institutionalization among the elderly
population leading to significant economic burden
[5, 6]. The 2016 direct costs for all individuals
diagnosed with AD were estimated at $221 billion,
including $150 billion to Medicare and Medicaid [1].
Other studies examining the economic burden of AD
have only assessed prevalent cases and have not com-
pared the current economic burden among treated
and untreated AD patients [7, 8]. Due to a scarcity
of information on specific AD-related outcomes, this
study evaluated all-cause mortality, rate of institu-
tionalization, and economic burden of treated versus




A retrospective analysis was performed using a
5% random national sample of the Medicare admin-
istrative database and Minimum Data Set (MDS)
from January 2010 through December 2014. The
MDS data was linked to Medicare data to assess
the overall health care utilization of AD patients.
MDS data includes severity proxy measurements,
such as the Cognitive Performance Scale (CPS),
and the Activities of Daily Living (ADL) Depen-




Patients aged 65–100 years and with at least 1
primary or at least 2 secondary diagnoses for AD
(International Classification of Disease 9th Edition
Clinical Modification [ICD-9-CM] code: 331.0) dur-
ing the identification period from January 2011 to
June 2014 were included in the primary analysis
cohort (Fig. 1). The first AD diagnosis date observed
during the identification period was designated as
the index date. Patients were also required to have
continuous health plan enrollment with medical and
pharmacy benefits for at least 12 months pre-index
date (baseline period) and at least 6 months post-
index date (follow-up period). Patient data were
assessed until the earliest of death, health plan
disenrollment, or the end of the study period.
Patients with diagnosis claims for AD, AD-related
dementia (ICD-9-CM: 290.xx, 294.xx, 331.1, 331.2,
331.7, 331.82, 331.89, 331.9, 797), or pharmacy
claims for an AD treatment (donepezil, rivastigmine,
galantamine, and memantine) during the baseline
period were excluded.
Patients were assigned to treated and untreated
cohorts based on AD treatment prescriptions within
6 months of index AD diagnosis during the follow-up
period.
Economic analysis population
Time-to-treatment analysis indicated that 10% of
the primary analysis population did not receive their
first AD treatment until 1 year or longer after their
diagnosis. Therefore, a subset of patients from the
primary analysis population was selected to analyze
economic outcomes, excluding the 10% who received
their first AD treatment 1 year or more after AD
diagnosis. This subset of patients was required to 1)
have continuous health plan enrollment with medical
and pharmacy benefits for at least 12 months pre-
index date and at least 12 months post-index date;
and 2) have received their first AD treatment within
6 months of their index AD diagnosis.
Study variables
Outcomes variables for primary analysis
population
Overall survival and rate of institutionalization
were the main end points of the primary analysis.
Overall survival was defined as patients who did not
die during the study period. Using the MDS data,
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patients who resided in a post-acute skilled nurs-
ing home (SNF) or nursing home for at least 120
consecutive days were considered institutionalized
[9]. Mortality and institutionalization rates during the
overall follow-up period were captured and estimated
in 100 person-years.
Outcomes variables for economic analysis
All-cause and AD-related dementia health care
resource use and costs were the main outcomes
for economic analysis. Claims were attributed to
AD-related dementia if they were associated with




included age, race, sex, and US geographical
region. Clinical characteristics included Charlson
Comorbidity Index (CCI) score [10] and individual
comorbid conditions during the 12 months prior to
the index date.
All-cause health care utilization and costs as well
as a number of diagnostic tests (magnetic reso-
nance imaging [MRI], positron emission tomography
[PET], and computed tomography [CT] scans) were
evaluated for the 12-month baseline period.
The CPS and ADL Dependency Scale were avail-
able for patients with linked MDS data. The CPS
has five components that address cognitive and com-
munication domains (memory, decision making, and
making self-understood), presence of coma, and eat-
ing dependency [11]. CPS scores range from 0 (intact)
to 6 (very severe impairment). The ADL-Short Form
(SF) includes four items (eating, personal hygiene,
toileting, and locomotion) [12]. The ADL-SF sums
the individual ADL items (rating of 0 to 4) into a scale
running from 0 to 16.
Statistical analysis
All study variables, including baseline and
outcome measures, were examined descriptively.
Numbers and percentages were provided for dichoto-
mous and polychotomous variables. Means and
standard deviations were provided for continuous
variables. For dichotomous and polychotomous vari-
ables, p-values were calculated according to the
chi-square test, and for continuous variables, t-tests
were used to calculate p-values.
In the primary analysis, a multivariable Cox pro-
portional hazard model with time dependent and
independent covariates was applied to estimate haz-
ard ratio (HR) and 95% confidence interval (CI)
of overall survival and rate of institutionaliza-
tion between treated and untreated AD patients.
Time independent covariates included patients’
socio-demographic and clinical characteristics. AD
treatment was included in the Cox model as a time-
dependent covariate.
In the economic analysis, possible confounders
of health care utilization and costs were controlled
using 1 : 1 propensity score matching (PSM) between
patients who received treatment within 6 months of




A total of 59,921 Medicare beneficiaries aged
between 65–100 years had an index diagnosis of AD
between January 2011 and June 2014. From this sam-
ple, 50,926 patients were excluded because they had
an AD or AD-related dementia diagnosis or were pre-
scribed AD treatment during the baseline period. A
total of 8,995 treatment na¨ive and newly-diagnosed
AD patients were selected for the primary analysis of
mortality and institutionalization (treated: n = 4,037;
untreated: n = 4,958; Fig. 1).
Approximately 44.8% of patients initiated treat-
ment (average 122 days post-AD diagnosis); mean
follow-up days for treated and untreated patients
was 681 versus 794 days, p < 0.0001. Treated
patients were prescribed donepezil (68.8%), meman-
tine (18.0%), rivastigmine (12.1%), and galantamine
(1.2%) as their first treatment. Of newly-diagnosed
AD patients, 74% were diagnosed in a physi-
cian’s office or outpatient hospital, and 18.2% were
diagnosed in an inpatient setting.
The untreated cohort included older patients (84.1
versus 81.6 years, p < 0.0001), with a greater propor-
tion of Caucasian (81.4% versus 80.4%, p = 0.2384)
and female patients (75.7% versus 72.5%,p = 0.0007)
compared to the treated cohort (Supplementary
Table 1). Supplementary Table 2 shows the base-
line clinical characteristics of newly-diagnosed AD
patients. At baseline, comorbid conditions such
as congestive heart failure (23.6% versus 14.6%,
p < 0.0001), peripheral vascular disease (16.9% ver-
sus 13.1%, p < 0.0001) and pneumonia (9.9% versus
6.0%, p < 0.0001) were generally more prevalent
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Fig. 1. Patient selection flow chart. AD, Alzheimer’s disease; PSM, propensity score matching. ∗ICD-9-CM diagnosis claim for AD:
331.0; ICD-9-CM diagnosis claim for AD-related dementia: 290.xx, 294.xx, 331.1, 331.2, 331.7, 331.82, 331.89, 331.9, 797. ‡ donepezil,
rivastigmine, galantamine, or memantine.
C.M. Black et al. / Burden of Incident AD Patients 189
Table 1
Cox model for time-to-death and time-to-institutionalization among newly-diagnosed AD patients (primary analysis population)
Time-to-Death Time-to-Institutionalization
Covariates HR (95% CI) p-value HR (95% CI) p-value
Index Treatment (Time-Dependent covariate)
Untreated (Reference)




75–84 1.76 (1.51, 2.06) <0.0001 1.154 (0.972, 1.37) 0.102
85–94 3.14 (2.71, 3.65) <0.0001 1.829 (1.549, 2.159) <0.0001
95–100 5.04 (4.20 6.06) <0.0001 1.983 (1.558, 2.525) <0.0001
Race
White (Reference)
Black 0.78 (0.68, 0.90) 0.0005 1.021 (0.861, 1.21) 0.815
Hispanic 0.69 (0.56, 0.85) 0.0004 0.571 (0.417, 0.781) 0.0005
Other (Asian/Native American) 0.66 (0.53, 0.83) 0.0003 0.999 (0.767, 1.302) 0.9961
Gender
Male (Reference)
Female 0.85 (0.77, 0.93) 0.0003 1.122 (0.989, 1.272) 0.0748
US Geographic Region
Northeast (Reference)
North Central 1.15 (1.02, 1.30) 0.0257 1.031 (0.886, 1.201) 0.692
South 1.15 (1.03, 1.28) 0.0134 0.902 (0.786, 1.034) 0.1392
West or Other 1.14 (1.00, 1.30) 0.0431 0.595 (0.495, 0.715) <0.0001
Baseline Comorbid Conditions
CCI Score 1.05 (1.03, 1.06) <0.0001 1.018 (0.999, 1.038) 0.0701
Individual Comorbidities
Parkinson’s Disease 1.01 (0.84, 1.22) 0.8964 0.956 (0.743, 1.229) 0.7238
Epilepsy 1.08 (0.89, 1.30) 0.4323 1.097 (0.852, 1.413) 0.4732
Mood Disorder 0.84 (0.76, 0.93) 0.0006 1.264 (1.115, 1.434) 0.0003
Pneumonia 1.32 (1.16, 1.50) <0.0001 1.1 (0.908, 1.334) 0.3305
Mild Cognitive Impairment 0.64 (0.48, 0.86) 0.0029 0.581 (0.404, 0.834) 0.0033
Cox model with time-dependent covariates was performed among Untreated n = 4,958 and Treated n = 4,037 cohorts. HR, hazard ratio; CI,
confidence interval; CCI, Charlson Comorbidity Index.
in the untreated cohort. In addition, the untreated
cohort had higher mean CCI scores (3.54 versus
3.22, p < 0.0001) and lower utilization of baseline
tests including computed tomography (CT) scan
(19.1% versus 22.6%, p < 0.0001) and magnetic reso-
nance imaging (MRI) (6.0% versus 12%, p < 0.0001)
compared to the treated cohort.
Approximately 1,915 AD patients resided in a SNF
facility or nursing home during the baseline period.
Untreated patients had higher baseline ADL scores
of 8.8 versus 7.4 (p < 0.0001) and CPS scores of
3.2 versus 2.0 (p < 0.0001) indicating more signifi-
cant impairment of daily function and cognition in
comparison to treated patients. A lower proportion
of patients in the untreated cohort had a diagnostic
test such as a CT scan or MRI during the baseline
period.
Outcome: Mortality
Untreated patients had a higher unadjusted inci-
dence rate of death (18.9 versus 9.9 per 100
person-years, p < 0.0001). After covariate adjustment
using Cox regression, patients were less likely to die
if they had ever received an AD treatment (adjusted
HR = 0.69, p < 0.0001, Table 1).
Outcome: Institutionalization
A larger proportion of untreated patients were
institutionalized at the time of diagnosis (10.5%
versus 4.3%, p < 0.0001). After their index AD
diagnosis, the untreated cohort had, on average, a
shorter time-to-institutionalization period (188.5 ver-
sus 283.1 days, p < 0.0001), and a higher rate of
institutionalization compared to the treated cohort
(11.0 versus 9.5 per 100 person-years, p = 0.0044).
After adjusting for baseline differences using Cox
regression, patients who received AD treatment
at any point were associated with a 20% lower
risk of being institutionalized (adjusted HR = 0.80,
p = 0.0003, Table 1). Older age and prior mood dis-
order diagnosis were risk factors associated with
institutionalization.
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Economic analysis
Patient characteristics
A total of 6,668 patients were further selected from
the primary analysis population if they had at least
12 months of follow-up. For the treatment cohort,
the first AD treatment claim was required to have
occurred within 6 months of the index AD diagno-
sis. A total of 6,330 patients were included in the
final economic analysis population (treated cohort:
n = 2,638; untreated cohort: n = 3,692; Fig. 1).
For patients in the treated cohort (n = 2,638), the
average number of days to initiate the first AD
treatment was 33 days (median: 10 days). Treated
patients were prescribed donepezil (70.9%), meman-
tine (15.9%), rivastigmine (11.9%), and galantamine
(1.3%) as their first treatment.
Untreated patients were older (83.6 versus 81.1
years, p < 0.0001) and had a higher proportion
of women (75.8% versus 72.6%, p = 0.0049) than
treated patients. Patients in the untreated cohort also
had a higher prevalence of key individual comor-
bidities as well as higher CCI scores (3.5 versus
3.1, p < 0.0001) compared to the treated cohort. The
results were similar to those observed within the pri-
mary analysis population (Supplementary Tables 3
and 4).
During the 12-month baseline period, the untreated
cohort had higher utilization for inpatient (25.0%
versus 18.4%, p < 0.0001), post-acute SNF (14.1%
versus 6.8%, p < 0.0001), home health agency
([HHA]; 19.3% versus 16.3%, p = 0.0022), and hos-
pice visits (3.1% versus 0.5%, p < 0.0001), but lower
utilization for outpatient office (86.1% versus 92.7%,
p < 0.0001) and outpatient hospital visits (66.6%
versus 73.3%, p < 0.0001), compared to the treated
cohort. The same trend was observed for health care
costs.
Economic outcomes
A 1 : 1 PSM was used to adjust for baseline
demographic and clinical characteristics between the
treated and the untreated patients. A total of 677
patients were matched from each cohort with well-
balanced baseline characteristics.
Monthly trends in total Medicare expenditures
spiked at the time of AD diagnosis (Fig. 2). The cost
differences between treated and untreated patients
were determined for the months leading up to the
diagnosis and continued to increase throughout the
span of the disease, especially in the first few months
immediately after the diagnosis. In fact, during the
month of diagnosis, untreated and treated AD patients
incurred significantly elevated health care costs, more
so in the untreated cohort, although not statistically
significant (mean $7,306 versus $6,308; p = 0.1059).
Inpatient and post-acute SNF care were the main cost
drivers of the Medicare expenditures incurred around
the time of diagnosis. Inpatient spending increased
significantly from the month leading up to diagno-
sis to the month of AD diagnosis (untreated: from
$334 to $3,039; treated: from $86 to $2,599; both
p < 0.0001); spending also increased for post-acute
SNF expenditure (untreated: $197 to $1,774; treated:
$93 to $1,774; all p < 0.0001).
The average annual total Medicare expenditures
(Fig. 3) were significantly higher among untreated
patients ($30,110 versus $25,828; p = 0.0162), driven
mostly by hospice care (cost difference = $2,658;
p < 0.0001). Inpatient and post-acute SNF costs were
important cost drivers; however, the cost differences
in inpatient ($658; p = 0.4252), and post-acute SNF
($1,124; p = 0.161) were not statistically significant
between untreated and treated patients. AD-related
health care costs accounted for 43% (untreated) and
48% (treated) of the total Medicare expenditures.
Treated patients compared to untreated patients had
significantly higher AD-related office costs ($457
versus $274; p < 0.0001). However, AD-related hos-
pice care and associated costs ($2,452 versus $322;
p < 0.0001) were significantly higher in the untreated
cohort.
A similar trend was observed in terms of health
care utilizations. Compared to treated patients,
untreated patients had significantly more hospice
visits (0.76 versus 0.17; p < 0.0001). On the other
hand, there were more outpatient office (14.88 ver-
sus 13.19; p = 0.0148) and pharmacy (31.79 versus
29.44; p = 0.0493) visits in treated patients com-
pared to untreated patients (Supplementary Table 5).
AD-related health care utilizations (Supplementary
Table 5) were substantially higher in treated patients
compared to untreated patients; except for hospice
care visits (0.57 versus 0.10; p < 0.0001) which were
higher in the untreated cohort.
DISCUSSION
This retrospective analysis was conducted to eval-
uate overall survival, rate of institutionalization, and
economic burden of treated versus untreated patients
newly diagnosed with AD. After controlling for
patient characteristics including comorbidities, we
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Fig. 2. PSM-adjusted all-cause average monthly cost among newly-diagnosed AD patients (economic analysis population). PSM, propensity
score matching model adjusting for age, race, gender, geographic region, Charlson Comorbidity Index score, baseline all-cause health care
utilization, baseline diagnostic tests (CT and MRI), and prevalence of individual comorbidities including Parkinson’s disease, epilepsy, mood
disorder, pneumonia, and mild cognitive impairment.
Fig. 3. Post-index PSM-adjusted annual all-cause and AD-related health care costs among newly-diagnosed AD patients (economic analysis
population). AD, Alzheimer’s disease; DME, durable medical equipment; ER, emergency room; HHA, home health agency; PSM, propensity
score matching model adjusting for age, race, gender, geographic region, Charlson Comorbidity Index score, baseline all-cause health care
utilization, baseline diagnostic tests (CT and MRI), and prevalence of individual comorbidities including Parkinson’s disease, epilepsy, mood
disorder, pneumonia, and mild cognitive impairment. ∗p < 0.05 treated versus untreated for all-cause health care costs; +p < 0.05 treated
versus untreated for AD-related cause health care costs.
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observed that newly-diagnosed AD patients who
received treatment had a lower risk of dying and being
institutionalized compared to untreated counterparts.
In addition, they incurred lower overall expenditures
of approximately $4,282 in total Medicare spending
for the 12 months post-AD diagnosis compared to
untreated patients. However, total AD-related costs
were only slightly lower for the treated cohort, and the
difference was not statistically significant. In addi-
tion, a large portion of the AD-related costs incurred
by the untreated AD patients was due to their AD-
related hospice care. Previous studies showed that
chronically ill patients with the ability and willing-
ness to manage their health and care are more likely
to adhere to or initiate treatment and, as a result,
incur lower health care costs [13, 14]. It is diffi-
cult to infer that the improved survival and lower
institutionalization rates were solely due to AD treat-
ment administration. However, the observed benefit
from the study findings suggests that receiving AD
treatment could be considered as a proxy for better
quality of care, access to care, and improved health
because patients who received AD therapy also most
likely received consistent medical attention for other
severe comorbidities. In general, AD patients get
sicker faster due to their condition, and the cost of
treating multiple complicated comorbidities results
in overall higher spending [15, 16].
Early detection of dementia is beneficial to provide
timely care and offer direct benefits to patients with
dementia [17]. However, our study showed that close
to 11% of untreated patients and approximately 4.3%
of treated patients were institutionalized at time of the
AD diagnosis. In addition, 67.8% of untreated AD
patients were diagnosed in ambulatory settings com-
pared to 81.2% of treated AD patients. This finding is
consistent with previous reports [18], implying that
many patients may receive their first AD diagnosis
when they meet a health care professional as a result
of another more serious health event. Furthermore,
untreated patients had lower numbers of physician
office and pharmacy visits, indicating a possible fail-
ure of ambulatory care management, which echoed
prior study findings [19, 20].
The current study found that Medicare total costs
in newly-diagnosed AD patients peaked significantly
during the month of diagnosis, and AD-related costs
accounted for 43–48% of the total Medicare expen-
ditures. This finding is similar to those of other
studies that examined the diagnostic pathways to
AD10 and Medicare expenditures for patients with
AD and AD-related dementia or MCI [21]. The
major cost components of Medicare expenditures
were found to be the use of inpatient and post-acute
SNF services post-AD diagnosis in our analysis.
Studies on hospital data have suggested that early
and timely detection of AD can be cost-saving
[6, 10, 22].
There were several limitations in this study. By
using retrospective claims data to identify newly-
diagnosed AD patients, these patients may represent
individuals across the spectrum of AD severity and
may not reflect results for patients with new onset
of AD. In addition, measures such as AD dura-
tion, disease severity and progression, cause of
death, patient health behaviors, and caregiver infor-
mation were not available in the Medicare data.
Furthermore, non-pharmacological treatment infor-
mation including computer cognitive training, diet,
and regular moderate exercise were unavailable in
the claims. Therefore, these estimates were not mea-
sured in our analysis. The lack of disease severity
data can lead to potential underestimation of the
severity of the disease of interest. However, we con-
trolled for the differences between the treated and
untreated cohorts using PSM, which created simi-
lar cohorts with well-balanced baseline demographic
and clinical characteristics.
Services reimbursed by Medicaid, such as custo-
dial care for patients who resided in a nursing facility
for more than 100 days, are not reflected in this anal-
ysis. Moreover, this study included fee-for-service
patients who had continuous enrollment in Medicare
Parts A and B, which may limit the generalizability of
the study results since patients enrolled in Medicare
Part C were not included.
A strict and robust inclusion criterion was applied
to capture newly-diagnosed AD patients by exclud-
ing patients who had an AD or dementia-related
diagnosis as well as patients who were prescribed
AD medications prior to the first index AD diagno-
sis. Although many patients receive AD treatment
without a diagnosis, this analysis assessed newly-
diagnosed AD patients. Prior AD or AD-related
diagnosis was the cause for most patient exclu-
sions (80%). The exclusion criterion was applied
in order to omit patients whose AD diagno-
sis may have manifested from other comorbid
diagnoses.
Since Medicare is the primary payer for elderly
patients in the United States, the results from our anal-
ysis are expected to reflect the health care resource
utilization and cost patterns of the elderly patient
population with newly-diagnosed AD.
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Conclusion
For patients who were newly diagnosed with AD,
initiation of treatment as close to diagnosis as possible
may translate to improved survival, lower institu-
tionalization rates, fewer resource utilizations, and
lower health care expenditures. Patients with newly-
diagnosed AD experience elevated health care costs,
mostly driven by hospital and post-acute skilled
nursing home visits during the period following diag-
nosis. This analysis suggests that early diagnosis,
better treatment and care management, especially in
an ambulatory setting, could be beneficial for AD
patients, caregivers, and the health care system from
both economic and clinical perspectives.
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